{"result": {"id": "fd714932-f4dc-4b5e-9655-8e90e208f618", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>P-GP<|>ORGANIZATION<|>P-gp is a protein that affects drug metabolism and transport, influencing the pharmacokinetics of various drugs like simvastatin and dabigatran etexilate\")  \n##\n(\"entity\"<|>辛伐他汀<|>PERSON<|>Simvastatin is a drug whose AUC is significantly increased when combined with P-gp inhibitors\")  \n##\n(\"entity\"<|>瑞舒伐他汀<|>PERSON<|>Rosuvastatin is a statin whose AUC and Cmax increase significantly when combined with cyclosporine due to OATP1B1 inhibition\")  \n##\n(\"entity\"<|>环孢素<|>PERSON<|>Cyclosporine is an immunosuppressant that inhibits OATP1B1, increasing the blood concentration of drugs like rosuvastatin\")  \n##\n(\"entity\"<|>OATP1B1<|>ORGANIZATION<|>Organic anion transporting polypeptide 1B1 is a transporter protein that affects drug uptake in the liver\")  \n##\n(\"entity\"<|>单硝酸异山梨酯<|>PERSON<|>Isosorbide mononitrate is a drug used for cardiovascular conditions, which can cause severe hypotension when combined with sildenafil\")  \n##\n(\"entity\"<|>胺碘酮<|>PERSON<|>Amiodarone is an antiarrhythmic drug whose metabolism can be accelerated by rifampin, reducing its therapeutic concentration\")  \n##\n(\"entity\"<|>西地那非<|>PERSON<|>Sildenafil is a vasodilator that can cause severe hypotension when combined with nitrates like isosorbide mononitrate\")  \n##\n(\"entity\"<|>利福平<|>PERSON<|>Rifampin is an antibiotic that induces CYP450 enzymes, accelerating the metabolism of drugs like amiodarone and ticagrelor\")  \n##\n(\"entity\"<|>替格瑞洛<|>PERSON<|>Ticagrelor is an antiplatelet drug whose metabolism is affected by CYP3A4 inhibitors and inducers\")  \n##\n(\"entity\"<|>利伐沙班<|>PERSON<|>Rivaroxaban is an anticoagulant metabolized by CYP3A4 and CYP2J2, with increased bleeding risk when combined with strong CYP3A4 inhibitors\")  \n##\n(\"entity\"<|>达比加群酯<|>PERSON<|>Dabigatran etexilate is a P-gp substrate whose AUC increases significantly when combined with P-gp inhibitors, increasing bleeding risk\")  \n##\n(\"relationship\"<|>P-GP<|>辛伐他汀<|>P-gp inhibition increases the AUC of simvastatin<|>7)  \n##\n(\"relationship\"<|>环孢素<|>瑞舒伐他汀<|>Cyclosporine inhibits OATP1B1, increasing rosuvastatin's blood concentration<|>8)  \n##\n(\"relationship\"<|>OATP1B1<|>瑞舒伐他汀<|>OATP1B1 is responsible for hepatic uptake of rosuvastatin<|>7)  \n##\n(\"relationship\"<|>单硝酸异山梨酯<|>西地那非<|>Combination causes severe hypotension due to synergistic vasodilation<|>9)  \n##\n(\"relationship\"<|>胺碘酮<|>利福平<|>Rifampin induces CYP450, reducing amiodarone's therapeutic concentration<|>6)  \n##\n(\"relationship\"<|>替格瑞洛<|>利福平<|>Rifampin induces CYP3A4, reducing ticagrelor's antiplatelet activity<|>6)  \n##\n(\"relationship\"<|>利伐沙班<|>CYP3A4<|>Rivaroxaban is metabolized by CYP3A4, increasing bleeding risk with inhibitors<|>7)  \n##\n(\"relationship\"<|>达比加群酯<|>P-GP<|>Dabigatran etexilate is a P-gp substrate, increasing AUC with inhibitors<|>8)  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166516, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 933, "prompt_tokens": 2526, "total_tokens": 3459, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 734}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: P-gp 而显著增加辛伐他汀的 AUC\t谨慎合用\n瑞舒伐他汀\t环孢素\t增加肌肉、肝脏 毒性\t合用环孢素使瑞舒伐他汀的 AUC 0 → 24 h  和 Cmax 分别增加和升高了近 7.1 和 10.6 倍\t　环孢素 显著 抑 制 OATP1B1，减 少肝 脏对瑞舒伐他汀的主动摄取，升高血 药浓度\t避免合用\n注：OATP1B1= 有机阳离子转运体\n表 4    心血管病治疗用药相关药物相互作用的潜在危害及处置\nTable 4     Potential risk and management of drug interactions in the treatment of cardiovascular diseases\n\n药物名称\t联合药物\t临床后果\t药动学改变\t相互作用机制\t临床建议\n单硝酸异山梨酯 胺碘酮\t　西地那非 利福平\t低血压\n降低疗效\t西地那非与单硝酸异山梨酯合用能显著降低血压\n利福平可能通过诱导 CYP450 同工酶加快胺碘酮 的代谢消除导致其低于治疗浓度\t　两种药物的扩张血管机制相同， 存在药效学的协同作用\n利福平可能通过诱导 CYP450 同 工酶而加快胺碘酮的代谢消除\t　避免合用 谨慎合用\n\n\n\n\nhttp://www.chinagp.net   E-mail:zgqkyx@chinagp.net.cn     ·3539 ·\n\n\n增强其降糖作用，临床应该谨慎合用。\n4.5.4     替 格 瑞 洛  替 格 瑞 洛 主 要 经 CYP3A4 代 谢， CYP3A4 强抑制剂（ 如克拉霉素、 伊曲康唑、 酮康唑 等）能减慢其代谢，增强抗血小板活性；利福平能诱导 CYP3A4 和 P-gp 降低其 AUC ，加快其代谢，显著减弱 其抗血小板活性。\n4.5.5    利伐沙班  利伐沙班通过 CYP3A4 、CYP2J2 和 非 CYP 依赖的机制进行代谢，与 CYP3A4 和 P-gp 强抑 制剂〔如酮康唑、伊曲康唑、伏立康唑、泊沙康唑等唑 类抗真菌药物或人类免疫缺陷病毒（HIV ）蛋白酶抑制 剂〕合用，可能增加出血风险，不建议合用。\n4.5.6    达比加群酯  达比加群酯是P-gp 的底物，与P-gp 抑制剂（如环孢素、伊曲康唑、决奈达隆）合用显著提 高达比加群酯的 AUC ，禁止合用；不推荐达比加群酯\n\n\n　与他克莫司合用，其他P-gp 强抑制剂如胺碘酮、奎尼丁、 维拉帕米等要谨慎合用。药效学方面，与其他 口服或注  射用抗凝药、抗血小板药（如普通肝素、低分子肝素、  磺达肝癸钠、华法林、利伐沙班、替格瑞洛）等合用可  增加出血风险；长期合用 NSAID 会使其出血\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_e9a900e7e860078ca9bf0f05e5bfdf6cdf24ebada04c75a35e5fb5318b0fa564_v2"}